Does COVID-19 Trigger the Risk for the Development of Parkinson’s Disease? Therapeutic Potential of Vitamin C

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Molecular Neurobiology

• Publication date

  2023-11-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12035-023-03756-3PMID 37957424
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• NXP032 ameliorates cognitive impairment by alleviating the neurovascular aging process in aged mouse brain

  2023cited by this paper
• SARS-CoV-2 susceptibility and COVID-19 illness course and outcome in people with pre-existing neurodegenerative disorders: systematic review with frequentist and Bayesian meta-analyses

  2023cited by this paper
• Lactobacillus plantarum CCFM405 against Rotenone-Induced Parkinson’s Disease Mice via Regulating Gut Microbiota and Branched-Chain Amino Acids Biosynthesis

  2023cited by this paper
• Gut Dysbiosis: A Target for Protective Interventions against Parkinson’s Disease

  2023cited by this paper
• COVID19-associated new-onset movement disorders: a follow-up study

  2023cited by this paper
• Parkinson's disease following COVID-19: six cases report.

  2023cited by this paper
• Gastrointestinal, Respiratory, and Olfactory Neurotropism of Sars-Cov2 as a Possible Trigger of Parkinson’s Disease: Is a Multi-Hit Multi-Step Process on the Cards

  2023cited by this paper
• Aptamer-conjugated gold nanoparticles and their diagnostic and therapeutic roles in cancer

  2023cited by this paper
• NXP031 prevents dopaminergic neuronal loss and oxidative damage in the AAV-WT-α-synuclein mouse model of Parkinson’s disease

  2022cited by this paper
• Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease

  2022cited by this paper
• Revealing the mystery of persistent smell loss in Long COVID patients

  2022cited by this paper
• Physical inactivity is associated with Parkinson's disease mild cognitive impairment and dementia

  2022cited by this paper
• Persistent neurological manifestations in long COVID-19 syndrome: A systematic review and meta-analysis

  2022cited by this paper
• Angiotensin type-1 receptor and ACE2 autoantibodies in Parkinson´s disease

  2022cited by this paper
• Cognitive and Neuropsychiatric Features of COVID-19 Patients After Hospital Dismission: An Italian Sample

  2022cited by this paper
• COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences

  2022cited by this paper
• Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson’s Disease: Insights into Mechanisms and Pathological Consequences

  2022cited by this paper
• Vitamin C Attenuates Oxidative Stress, Inflammation, and Apoptosis Induced by Acute Hypoxia through the Nrf2/Keap1 Signaling Pathway in Gibel Carp (Carassius gibelio)

  2022cited by this paper
• Role of SARS-CoV-2 in Modifying Neurodegenerative Processes in Parkinson’s Disease: A Narrative Review

  2022cited by this paper
• ER Stress in COVID-19 and Parkinson’s Disease: In Vitro and In Silico Evidences

  2022cited by this paper
• SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro

  2022cited by this paper
• Long-term cognitive impairments following COVID-19: a possible impact of hypoxia

  2022cited by this paper
• Viral load is associated with mitochondrial dysfunction and altered monocyte phenotype in acute severe SARS-CoV-2 infection

  2022cited by this paper
• SARS-CoV-2 ORF3a induces RETREG1/FAM134B-dependent reticulophagy and triggers sequential ER stress and inflammatory responses during SARS-CoV-2 infection

  2022cited by this paper
• Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study

  2022cited by this paper
• Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients

  2022cited by this paper
• Acute akinetic-rigid syndrome in COVID-19 encephalitis

  2022cited by this paper
• Vitamin C protects against hypoxia, inflammation, and ER stress in primary human preadipocytes and adipocytes.

  2022cited by this paper
• COVID-19 infection presented as severe dyskinesia in a patient with Parkinson’s disease: a case with daily video recording

  2022cited by this paper
• COVID-19 and Physical Activity Behaviour in People with Neurological Diseases: A Systematic Review

  2022cited by this paper
• Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis

  2022cited by this paper
• NXP032 Ameliorates Aging-Induced Oxidative Stress and Cognitive Impairment in Mice through Activation of Nrf2 Signaling

  2022cited by this paper
• The possible role of ursolic acid in Covid-19: A real game changer

  2022cited by this paper
• Potential Therapeutic Use of the Rosemary Diterpene Carnosic Acid for Alzheimer’s Disease, Parkinson’s Disease, and Long-COVID through NRF2 Activation to Counteract the NLRP3 Inflammasome

  2022cited by this paper
• Neuronal Oxidative Stress Promotes α-Synuclein Aggregation In Vivo

  2022cited by this paper
• SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein

  2022cited by this paper
• Natural and Semi-Synthetic Flavonoid Anti-SARS-CoV-2 Agents for the Treatment of Long COVID-19 Disease and Neurodegenerative Disorders of Cognitive Decline.

  2022cited by this paper
• Multifunctional role of natural products for the treatment of Parkinson’s disease: At a glance

  2022cited by this paper
• Fibrinogen, Fibrin, and Fibrin Degradation Products in COVID-19.

  2022cited by this paper
• Vitamin C Deficiency in Blood Samples of COVID-19 Patients

  2022cited by this paper
• New-onset Parkinsonism as a Covid-19 infection sequela: A systematic review and meta-analysis

  2022cited by this paper
• Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial

  2021cited by this paper
• Diseases

  2021cited by this paper
• Favourable course in a cohort of Parkinson’s disease patients infected by SARS-CoV-2: a single-centre experience

  2021cited by this paper
• Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection

  2021cited by this paper
• COVID-19 associated central nervous system manifestations, mental and neurological symptoms: a systematic review and meta-analysis

  2021cited by this paper
• The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study

  2021cited by this paper
• COVID-19 and Parkinson’s Disease: What Do We Know So Far?

  2021cited by this paper
• The Association between Serum Oxidative Stress Indexes and Pathogenesis of Parkinson’s Disease in the Northwest of Iran

  2021cited by this paper
• Antioxidant Therapeutics in Parkinson’s Disease: Current Challenges and Opportunities

  2021cited by this paper
• Cytokine Profile in Plasma Extracellular Vesicles of Parkinson’s Disease and the Association with Cognitive Function

  2021cited by this paper
• Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue

  2021cited by this paper
• Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City

  2021cited by this paper
• Dementia is an age‐independent risk factor for severity and death in COVID‐19 inpatients

  2021cited by this paper
• Silent hypoxia in COVID-19: pathomechanism and possible management strategy

  2021cited by this paper
• Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression

  2021cited by this paper
• Clinical Profiles and Mortality of COVID‐19 Inpatients with Parkinson's Disease in Germany

  2021influential reference
• Factors associated with COVID‐19 in people with Parkinson’s disease: a systematic review and meta‐analysis

  2021cited by this paper
• Unexplained worsening of parkinsonian symptoms in a patient with advanced Parkinson’s disease as the sole initial presentation of COVID-19 infection: a case report

  2021cited by this paper
• The Intersection of Parkinson’s Disease, Viral Infections, and COVID-19

  2021cited by this paper
• Neurological Implications of COVID-19: Role of Redox Imbalance and Mitochondrial Dysfunction

  2021cited by this paper
• Dietary Approaches to Improve Efficacy and Control Side Effects of Levodopa Therapy in Parkinson's Disease: A Systematic Review

  2021cited by this paper
• NOX2 Activation in COVID-19: Possible Implications for Neurodegenerative Diseases

  2021cited by this paper
• Outcome of Hospitalized Parkinson's Disease Patients with and without COVID‐19

  2021cited by this paper
• Pulmonary coagulation and fibrinolysis abnormalities that favor fibrin deposition in the lungs of mouse antibody-mediated transfusion-related acute lung injury

  2021cited by this paper
• Fibrin Clot Formation under Oxidative Stress Conditions

  2021cited by this paper
• Post‐COVID worsening of a Parkinson's disease patient

  2021cited by this paper
• The impact of Parkinson's disease on manifestations and outcomes of Covid‐19 patients: A systematic review and meta‐analysis

  2021cited by this paper
• Prolonged Dysphagia After a COVID-19 Infection in a Patient With Parkinson Disease

  2021cited by this paper
• The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson’s Disease: An Updated Systematic Review

  2021cited by this paper
• Hypoxia Signaling in Parkinson’s Disease: There Is Use in Asking “What HIF?”

  2021cited by this paper
• COVID-19 manifestations in people with Parkinson’s disease: a USA cohort

  2021cited by this paper
• Characteristics and Outcomes of Parkinson's Disease Individuals Hospitalized with COVID‐19 in a New York City Hospital System

  2021cited by this paper
• A triple‐blind, placebo‐controlled, randomized clinical trial to evaluate the effect of curcumin‐containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID‐19 patients

  2021cited by this paper
• Sars-Cov-19 associated with aspiration pneumonia in a patient with Parkinson disease: A case report

  2021cited by this paper
• Herbal medicine use for the management of COVID-19: A review article

  2021cited by this paper
• Baicalein protects against MPP+/MPTP-induced neurotoxicity by ameliorating oxidative stress in SH-SY5Y cells and mouse model of Parkinson's disease.

  2021cited by this paper
• Aptamer Applications in Neuroscience

  2021cited by this paper
• Movement Disorders Associated with COVID-19

  2021cited by this paper
• Inflammatory Response Modulation by Vitamin C in an MPTP Mouse Model of Parkinson’s Disease

  2021cited by this paper
• α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission

  2021cited by this paper
• The Effect of Vitamin C on Pathological Parameters and Survival Duration of Critically Ill Coronavirus Disease 2019 Patients: A Randomized Clinical Trial

  2021cited by this paper
• The Effects of Vitamin C on the Multiple Pathophysiological Stages of COVID-19

  2021cited by this paper
• Knowledge about COVID-19 and beliefs about and use of herbal products during the COVID-19 pandemic: A cross-sectional study in Saudi Arabia

  2020cited by this paper
• Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

  2020cited by this paper
• Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia

  2020cited by this paper
• [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].

  2020cited by this paper
• SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

  2020cited by this paper
• [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia].

  2020cited by this paper
• Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

  2020cited by this paper
• Dietary antioxidants associated with slower progression of parkinsonian signs in older adults

  2020cited by this paper
• Effects of COVID‐19 on Parkinson's Disease Clinical Features: A Community‐Based Case‐Control Study

  2020cited by this paper
• COVID‐19 in Parkinson’s Disease Patients Living in Lombardy, Italy

  2020cited by this paper
• Neurological Manifestations of COVID‐19: A systematic review and current update

  2020cited by this paper
• On the effect of vitamin C intake on human health: How to (mis)interprete the clinical evidence

  2020cited by this paper
• The international European Academy of Neurology survey on neurological symptoms in patients with COVID‐19 infection

  2020cited by this paper
• Coagulopathy in COVID‐19

  2020cited by this paper
• Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection

  2020cited by this paper
• The use of IV vitamin C for patients with COVID-19: a case series

  2020cited by this paper
• The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease

  2020cited by this paper

• Ocular neuroinflammatory response secondary to SARS-CoV-2 infection-a review

  2025cites this paper
• Vitamin C reduces the loss of retinal ganglion cells in chronic glaucoma by inhibiting neuroinflammation

  2025cites this paper
• Neurological complications caused by SARS-CoV-2

  2024cites this paper
• Potential hypothesis for the increased risk of Parkinson´s disease following COVID-19

  2024cites this paper
• SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms

  2024cites this paper